414 related articles for article (PubMed ID: 32312419)
41. Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity.
Premnath PN; Craig SN; Liu S; Anderson EL; Grigoroudis AI; Kontopidis G; Perkins TL; Wyatt MD; Pittman DL; McInnes C
J Med Chem; 2015 Jan; 58(1):433-42. PubMed ID: 25454794
[TBL] [Abstract][Full Text] [Related]
42. Cell cycle regulation by long non-coding RNAs.
Kitagawa M; Kitagawa K; Kotake Y; Niida H; Ohhata T
Cell Mol Life Sci; 2013 Dec; 70(24):4785-94. PubMed ID: 23880895
[TBL] [Abstract][Full Text] [Related]
43. Cyclin-dependent kinase inhibitors: novel anticancer agents.
Mani S; Wang C; Wu K; Francis R; Pestell R
Expert Opin Investig Drugs; 2000 Aug; 9(8):1849-70. PubMed ID: 11060782
[TBL] [Abstract][Full Text] [Related]
44. Selective inhibition of proteins regulating CDK/cyclin complexes: strategy against cancer--a review.
Sarita Rajender P; Ramasree D; Bhargavi K; Vasavi M; Uma V
J Recept Signal Transduct Res; 2010 Aug; 30(4):206-13. PubMed ID: 20560705
[TBL] [Abstract][Full Text] [Related]
45. Cyclin-dependent kinases: inhibition and substrate recognition.
Endicott JA; Noble ME; Tucker JA
Curr Opin Struct Biol; 1999 Dec; 9(6):738-44. PubMed ID: 10607671
[TBL] [Abstract][Full Text] [Related]
46. Targeting cyclin-dependent kinases in anti-neoplastic therapy.
Bruyère C; Meijer L
Curr Opin Cell Biol; 2013 Dec; 25(6):772-9. PubMed ID: 24011867
[TBL] [Abstract][Full Text] [Related]
47. Naturally Sourced CDK Inhibitors and Current Trends in Structure-Based Synthetic Anticancer Drug Design by Crystallography.
Nandi S; Dey R; Dey S; Samadder A; Saxena AK
Anticancer Agents Med Chem; 2022; 22(3):485-498. PubMed ID: 34503422
[TBL] [Abstract][Full Text] [Related]
48. Structure and inhibitor specificity of the PCTAIRE-family kinase CDK16.
Dixon-Clarke SE; Shehata SN; Krojer T; Sharpe TD; von Delft F; Sakamoto K; Bullock AN
Biochem J; 2017 Feb; 474(5):699-713. PubMed ID: 28057719
[TBL] [Abstract][Full Text] [Related]
49. Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kip1, to regions involved in human cancer.
Bullrich F; MacLachlan TK; Sang N; Druck T; Veronese ML; Allen SL; Chiorazzi N; Koff A; Heubner K; Croce CM
Cancer Res; 1995 Mar; 55(6):1199-205. PubMed ID: 7882308
[TBL] [Abstract][Full Text] [Related]
50. Cyclin-dependent kinases in cancer: Role, regulation, and therapeutic targeting.
Gupta A; Dagar G; Chauhan R; Sadida HQ; Almarzooqi SK; Hashem S; Uddin S; Macha MA; Akil ASA; Pandita TK; Bhat AA; Singh M
Adv Protein Chem Struct Biol; 2023; 135():21-55. PubMed ID: 37061333
[TBL] [Abstract][Full Text] [Related]
51. Formation of p27-CDK complexes during the human mitotic cell cycle.
Soos TJ; Kiyokawa H; Yan JS; Rubin MS; Giordano A; DeBlasio A; Bottega S; Wong B; Mendelsohn J; Koff A
Cell Growth Differ; 1996 Feb; 7(2):135-46. PubMed ID: 8822197
[TBL] [Abstract][Full Text] [Related]
52. Characterization of murine gammaherpesvirus 68 v-cyclin interactions with cellular cdks.
Upton JW; van Dyk LF; Speck SH
Virology; 2005 Oct; 341(2):271-83. PubMed ID: 16102793
[TBL] [Abstract][Full Text] [Related]
53. Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Blachly JS; Byrd JC; Grever M
Semin Oncol; 2016 Apr; 43(2):265-73. PubMed ID: 27040705
[TBL] [Abstract][Full Text] [Related]
54. Cell cycle, CDKs and cancer: a changing paradigm.
Malumbres M; Barbacid M
Nat Rev Cancer; 2009 Mar; 9(3):153-66. PubMed ID: 19238148
[TBL] [Abstract][Full Text] [Related]
55. Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer.
Balakrishnan A; Vyas A; Deshpande K; Vyas D
World J Gastroenterol; 2016 Feb; 22(7):2159-64. PubMed ID: 26900281
[TBL] [Abstract][Full Text] [Related]
56. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
[TBL] [Abstract][Full Text] [Related]
57. Highly potent p21(WAF1)-derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A.
Zheleva DI; McInnes C; Gavine AL; Zhelev NZ; Fischer PM; Lane DP
J Pept Res; 2002 Nov; 60(5):257-70. PubMed ID: 12383116
[TBL] [Abstract][Full Text] [Related]
58. Transforming activity of Fbxo7 is mediated specifically through regulation of cyclin D/cdk6.
Laman H; Funes JM; Ye H; Henderson S; Galinanes-Garcia L; Hara E; Knowles P; McDonald N; Boshoff C
EMBO J; 2005 Sep; 24(17):3104-16. PubMed ID: 16096642
[TBL] [Abstract][Full Text] [Related]
59. Molecules inducing specific cyclin-dependent kinase degradation and their possible use in cancer therapy.
Zheng M; Zhang XY; Chen W; Xia F; Yang H; Yuan K; Yang P
Future Med Chem; 2024 Feb; 16(4):369-388. PubMed ID: 38288571
[TBL] [Abstract][Full Text] [Related]
60. Long Noncoding RNAs Regulate Cell Growth, Proliferation, and Apoptosis.
Li J; Tian H; Yang J; Gong Z
DNA Cell Biol; 2016 Sep; 35(9):459-70. PubMed ID: 27213978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
